DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Hypoglycemia Associated Autonomic Failure in Type 1 DM

Information source: Vanderbilt University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 1 Diabetes

Intervention: Fluoxetine (Drug); Placebo (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Stephen N. Davis, MD, Principal Investigator, Affiliation: Vanderbilt University

Summary

It is unclear what effect selective serotonin reuptake inhibitors (SSRIs) have on hypoglycemia. Thus, the American Hospital Formulary Service recommends careful monitoring of blood glucose levels in all patients with diabetes initiating or discontinuing SSRIs (Katz et al., 1996). Because of the increased prevalence of depression in those with diabetes, it is critical to discover what affect the antidepressant therapy may have on counterregulatory responses to hypoglycemia. This study hypothesizes that chronic administration of SSRIs may result in a blunted counterregulatory response to hypoglycemia, thereby leaving individuals more susceptible to hypoglycemia.

Clinical Details

Official title: Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6

Study design: Other, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment

Primary outcome: Catecholamine measures

Detailed description: Because selective serotonin reuptake inhibitors are commonly prescribed to treat depression, it is vital to understand how these antidepressants affect hypoglycemia- the most feared complication in diabetes. This study's aim is to determine whether individuals who are chronically taking selective serotonin reuptake inhibitors have a reduced ability to defend against hypoglycemia compared to individuals not taking the medication, thus leaving them more susceptible to hypoglycemia. Both healthy volunteers and volunteers with type 1 diabetes mellitus will be studied. The results could potentially be important to diabetic patients, by demonstrating to physicians how to modify therapy for those taking antidepressants in order to avoid hypoglycemia.

The known effects of SSRI on the hypothalamo pituitary axis(HPA)may be important to the counterregulation of hypoglycemia. Prior research has demonstrated in healthy volunteers that antecedent increases in plasma cortisol result in significant blunting of neuroendocrine and autonomic responses to subsequent hypoglycemia. Thus, by activating the HPA axis, SSRIs could cause blunting of the counterregulatory response to hypoglycemia.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 16 (8 males, 8 females) healthy volunteers aged 18-45 yr

- 34 (17 males, 17 females) type 1 diabetes volunteers aged 18-45 yr

- Body mass index 21-30 kg • m-2

- Normal bedside autonomic function

- Normal results of routine blood test to screen for hepatic, renal, and hematological

abnormalities

- Female volunteers of childbearing potential: negative HCG pregnancy test

- Volunteers over 40 years old: normal heart tracing recorded while resting and walking

on the treadmill

- For those with type 1 diabetes: HbA1c > 7. 0%

- For those with type 1 diabetes: had diabetes for 2-15 years

- For those with type 1 diabetes: no clinical evidence of diabetic tissue

complications

Exclusion Criteria:

- Prior history of poor health: any current or prior disease condition that alters

carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease

- Hemoglobin of less than 12 g/dl

- Abnormal results following screening tests

- Pregnancy

- Subjects with any indication of depression, anxiety, bipolar, panic, or eating

disorders

- Subjects with a past medical history or family history of mania or bipolar disorders

- Subjects unable to give voluntary informed consent

- Subjects with a recent medical illness

- Subjects with known liver or kidney disease

- Subjects taking steroids

- Subjects taking beta blockers

- Subjects on anticoagulant drugs, anemic, or with known bleeding diseases

Locations and Contacts

Vanderbilt University, Nashville, Tennessee 37232-0475, United States
Additional Information

Starting date: March 2005
Ending date: June 2009
Last updated: January 1, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008